162 related articles for article (PubMed ID: 23574730)
1. Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus.
Okada K; Yagyu H; Kotani K; Yamazaki H; Ozaki K; Takahashi M; Nagashima S; Osuga J; Ishibashi S
Endocr J; 2013; 60(7):913-22. PubMed ID: 23574730
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
3. Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Imai C; Saito M; Mochizuki K; Fuchigami M; Goda T; Osonoi T
Metabolism; 2014 Jun; 63(6):746-53. PubMed ID: 24559582
[TBL] [Abstract][Full Text] [Related]
4. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
5. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
[TBL] [Abstract][Full Text] [Related]
6. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.
Aoki K; Masuda K; Miyazaki T; Togashi Y; Terauchi Y
Endocr J; 2010; 57(8):667-72. PubMed ID: 20519806
[TBL] [Abstract][Full Text] [Related]
7. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
Kimura T; Suzuki J; Ichikawa M; Imagawa M; Sato S; Fujii M; Zenimaru Y; Inaba S; Takahashi S; Konoshita T; Miyamori I
Diabetes Technol Ther; 2012 Jul; 14(7):545-51. PubMed ID: 22519736
[TBL] [Abstract][Full Text] [Related]
9. Effect of miglitol as an add-on to bolus insulin on postprandial glycemic excursions in type 2 diabetes patients assessed by continuous glucose monitoring.
Matsuura K; Mori Y; Nakamura A; Yokoyama J; Utsunomiya K
Diabetes Technol Ther; 2012 May; 14(5):423-9. PubMed ID: 22316114
[TBL] [Abstract][Full Text] [Related]
10. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
Mori Y; Taniguchi Y; Miyazaki S; Yokoyama J; Utsunomiya K
Diabetes Technol Ther; 2013 Mar; 15(3):237-40. PubMed ID: 23402316
[TBL] [Abstract][Full Text] [Related]
11. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
Tremblay AJ; Lamarche B; Deacon CF; Weisnagel SJ; Couture P
Diabetes Obes Metab; 2011 Apr; 13(4):366-73. PubMed ID: 21226820
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment.
Baek JH; Jin SM; Kaku K; Jung JA; Kim JR; Ko JW; Kim MJ; Lee SY; Huh WS; Kim JH
Expert Opin Pharmacother; 2015 Jun; 16(8):1127-36. PubMed ID: 25881690
[TBL] [Abstract][Full Text] [Related]
13. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K
Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736
[TBL] [Abstract][Full Text] [Related]
14. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
15. Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".
Mikada A; Narita T; Yokoyama H; Yamashita R; Horikawa Y; Tsukiyama K; Yamada Y
Diabetes Res Clin Pract; 2014 Dec; 106(3):538-47. PubMed ID: 25451890
[TBL] [Abstract][Full Text] [Related]
16. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
17. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus.
Jung JA; Kaku K; Kim JH; Kim JR; Ko JW; Lee SY; Huh W
Adv Ther; 2013 Nov; 30(11):1018-29. PubMed ID: 24249434
[TBL] [Abstract][Full Text] [Related]
18. Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study.
Seo C; Sakamoto M; Nishimura R; Tsujino D; Ando K; Morimoto A; Utsunomiya K
Diabetes Technol Ther; 2013 May; 15(5):378-85. PubMed ID: 23634671
[TBL] [Abstract][Full Text] [Related]
19. Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus.
Yokoyama H; Kannno S; Ishimura I; Node K
Metabolism; 2007 Nov; 56(11):1458-63. PubMed ID: 17950094
[TBL] [Abstract][Full Text] [Related]
20. Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.
Tatsumi F; Hashiramoto M; Hirukawa H; Kimura T; Shimoda M; Tawaramoto K; Kanda-Kimura Y; Anno T; Kawasaki F; Mune T; Matsuki M; Kaku K
Diabetes Res Clin Pract; 2013 Jul; 101(1):35-44. PubMed ID: 23711593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
